Completed PHASE1/PHASE2 INTERVENTIONAL 9-arm NCT03803202

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

A Phase 1/2, Randomized, Single Ascending Dose Study in Adults (Stage 1) and Randomized, Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, a Pneumococcal Vaccine

Sponsor: Affinivax, Inc.

Conditions Healthy Volunteers Pneumococcal Disease Pneumonia, Bacterial

Interventions ASP3772 PCV13 PPSV23

Updated 26 times since 2019 Last updated: Nov 30, 2023 Started: Jan 24, 2019 Primary completion: Sep 28, 2020 Completion: Sep 28, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Healthy Volunteers and Pneumococcal Disease and is currently completed. Affinivax, Inc. leads this study, which shows 26 recorded versions since 2019 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

26 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
May 2022 — Jan 2024 [monthly]

Completed PHASE1_PHASE2

▶ Show 21 earlier versions

Apr 2022 — May 2022 [monthly]

Completed PHASE1_PHASE2
Oct 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2
Feb 2021 — Oct 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE1_PHASE2
Dec 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Nov 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2020 — Nov 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2
Aug 2020 — Sep 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
May 2020 — Jun 2020 [monthly]

Recruiting PHASE1_PHASE2
Apr 2020 — May 2020 [monthly]

Recruiting PHASE1_PHASE2
Mar 2020 — Apr 2020 [monthly]

Recruiting PHASE1_PHASE2
Jan 2020 — Mar 2020 [monthly]

Recruiting PHASE1_PHASE2
Dec 2019 — Jan 2020 [monthly]

Recruiting PHASE1_PHASE2
Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE1_PHASE2
Oct 2019 — Nov 2019 [monthly]

Recruiting PHASE1_PHASE2
Jul 2019 — Oct 2019 [monthly]

Recruiting PHASE1_PHASE2
Jun 2019 — Jul 2019 [monthly]

Recruiting PHASE1_PHASE2
May 2019 — Jun 2019 [monthly]

Recruiting PHASE1_PHASE2
Mar 2019 — May 2019 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2019 — Mar 2019 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Affinivax, Inc.
GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Banning, United States , Binghamton, United States , Cedar Park, United States , Fort Worth, United States , Hollywood, United States , Houston, United States , Knoxville, United States , McKinney, United States , Norfolk, United States , Pearland, United States and 13 more locations